Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.

The post Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials appeared first on MedCity News.

Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression.

The post Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF appeared first on MedCity News.

A data safety monitoring board recommended pausing the Phase 2b test of Pliant’s bexotegrast, an experimental treatment for idiopathic pulmonary fibrosis. The move follows a prespecified data review, the company said.

The post Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug appeared first on MedCity News.

Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning a regulatory submission supported by its IPF drug’s Phase 3 data.

The post AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead appeared first on MedCity News.

Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.

The post J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS appeared first on MedCity News.

Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.

The post With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO appeared first on MedCity News.

FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.

The post FibroGen’s Fibrosis Drug Flunks Again in Phase 3, Triggering Cost-Cutting Moves appeared first on MedCity News.

AbbVie acquired DJS Antibodies for $255 million up front. The U.K.-based biotech’s lead program is an antibody drug in preclinical development for idiopathic pulmonary fibrosis, a chronic lung disorder with few FDA-approved treatments.

The post AbbVie pays $255M to buy a biotech with drug candidate for fatal lung disorder appeared first on MedCity News.

Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.

The post Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis appeared first on MedCity News.

A NeRRE Therapeutics drug that failed a clinical trial for refractory or unexplained chronic cough is getting a second shot as a potential treatment for chronic cough in patients with idiopathic pulmonary fibrosis, a rare lung disorder. The biotech raised £20M to proceed with Phase 2 testing.

The post NeRRe nabs £20M to test chronic cough drug in patients with a fatal lung disease appeared first on MedCity News.

The collaboration includes six drugs in development and more than 20 in preclinical development. It also amends an existing four-year-old partnership the two companies had regarding the autoimmune disease drug filgotinib.

The post Gilead, Galapagos sign $5.05B drug-development deal appeared first on MedCity News.

Health tech incubator MATTER has joined forces with Three Lakes Partners to launch an innovation challenge to meet the needs of idiopathic pulmonary fibrosis patients.

The post A $1M innovation challenge seeks quality-of-life solutions for IPF patients appeared first on MedCity News.

The post Third Rock funnels $45M into Pliant Therapeutics to develop small molecule drugs for fibrosis appeared first on MedCity News.

The post Cancer and heart disease dominate Cleveland Clinic’s Top 10 Medical Innovations for 2015 appeared first on MedCity News.

The post ImmuneWorks has a lung transplant therapy in the works appeared first on MedCity News.